ANTONI RIBAS, MD
Osteopathic Medicine at 120, Los Angeles, CA
License number
California A76097
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
200 120Th St, Los Angeles, CA 90095
Phone
(310) 206-3928
(310) 825-2493 (Fax)
(310) 825-2493 (Fax)
Personal information
See more information about ANTONI RIBAS at radaris.comName
Address
Phone
Los Angeles, CA
10724 Wilshire Blvd, Los Angeles, CA 90024
Organization information
See more information about ANTONI RIBAS at bizstanding.comAntoni Ribas MD
100 Ucla Medical Plz, Los Angeles, CA 90024
Industry:
Internist
Phone:
(310) 794-4955 (Phone)
Antoni Ribas
Professional information
Dr. Antoni Ribas, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Hematology, Hematology & Oncology
Address:
UCLA Oncology Hematology
100 Medical Plz SUITE 550, Los Angeles 90095
(310) 206-8516 (Phone)
UCLA Oncology Hematology
100 Ucla Medical Plz SUITE 550, Los Angeles 90024
(310) 794-4955 (Phone)
100 Medical Plz SUITE 550, Los Angeles 90095
(310) 206-8516 (Phone)
UCLA Oncology Hematology
100 Ucla Medical Plz SUITE 550, Los Angeles 90024
(310) 794-4955 (Phone)
Languages:
English
Hospitals:
UCLA Oncology Hematology
100 Medical Plz SUITE 550, Los Angeles 90095
UCLA Oncology Hematology
100 Ucla Medical Plz SUITE 550, Los Angeles 90024
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
UCLA Medical Center, Santa Monica
1250 16Th St, Santa Monica 90404
100 Medical Plz SUITE 550, Los Angeles 90095
UCLA Oncology Hematology
100 Ucla Medical Plz SUITE 550, Los Angeles 90024
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
UCLA Medical Center, Santa Monica
1250 16Th St, Santa Monica 90404
Education:
Medical School
Universidad De Barcelona, Facultad De Medicina
Graduated: 1990
Universidad De Barcelona, Facultad De Medicina
Graduated: 1990
Antoni Ribas, Los Angeles CA
Specialties:
Hematology & Oncology, Medical Oncology, Hematology
Work:
Ucla Dept Medicine Professional Group
100 Ucla Medical Plz, Los Angeles, CA 90024 University of California at Los Angeles
100 Medical Plz, Los Angeles, CA 90095
100 Ucla Medical Plz, Los Angeles, CA 90024 University of California at Los Angeles
100 Medical Plz, Los Angeles, CA 90095
Education:
Universidad De Barcelona (1990)
Associate Professor At Ucla
Position:
Associate Professor at UCLA
Location:
Greater Los Angeles Area
Industry:
Medical Practice
Work:
UCLA
-
Associate Professor
Education:
Universitat de Barcelona 1995 - 1999
Compositions And Methods For Detection And Treatment Of B-Raf Inhibitor-Resistant Melanomas
US Patent:
2013021, Aug 22, 2013
Filed:
Nov 18, 2011
Appl. No.:
13/879302
Inventors:
Roger S. Lo - Los Angeles CA, US
Antoni Ribas - Los Angeles CA, US
Antoni Ribas - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/574, A61K 31/437, A61K 45/06, C12Q 1/68
US Classification:
514300, 435 612, 435 79, 506 9
Abstract:
Specific, targetable molecules mediating acquired resistance of B-RAF-mutant melanomas to a B-RAF inhibitor, thereby providing materials and methods for the treatment and detection of B-RAF inhibitor resistant cancers, such as melanoma. A method of identifying a patient to be treated with an alternative to B-RAF inhibitor therapy is described. Also described is a method of treating a patient having cancer. The patient is administered a MEK inhibitor, optionally in conjunction with vemurafenib therapy, or an inhibitor of the MAPK pathway (RAF, MEK, ERK) in conjunction with an inhibitor of the RTK-PI3K-AKT-mTOR pathway.
Capture Agents And Related Methods And Systems For Detecting And/Or Sorting Targets
US Patent:
8394590, Mar 12, 2013
Filed:
Oct 8, 2010
Appl. No.:
12/901151
Inventors:
Gabriel A. Kwong - Alhambra CA, US
Caius G. Radu - Los Angeles CA, US
Owen Witte - Sherman Oaks CA, US
James R. Heath - South Pasadena CA, US
Antoni Ribas - Los Angeles CA, US
Caius G. Radu - Los Angeles CA, US
Owen Witte - Sherman Oaks CA, US
James R. Heath - South Pasadena CA, US
Antoni Ribas - Los Angeles CA, US
Assignee:
California Institute of Technology - Pasadena CA
University of California - Oakland CA
University of California - Oakland CA
International Classification:
C12Q 1/68
US Classification:
435 612, 435 71, 4352872
Abstract:
Polynucleotide-encoded capture agents for target detection and in particular modular polynucleotide-capture agents comprising a target binding component, a scaffold component and an encoding component formed by standardized molecular units that can be coupled and decoupled in a controlled fashion, and related compositions methods and systems.
Mart-1 T Cell Receptors
US Patent:
2008019, Aug 21, 2008
Filed:
Sep 28, 2007
Appl. No.:
11/864841
Inventors:
Lili Yang - Pasadena CA, US
David Baltimore - Pasadena CA, US
Pin Wang - Pasadena CA, US
James Economou - Pacific Palisades CA, US
Antoni Ribas - Los Angeles CA, US
David Baltimore - Pasadena CA, US
Pin Wang - Pasadena CA, US
James Economou - Pacific Palisades CA, US
Antoni Ribas - Los Angeles CA, US
International Classification:
A61K 45/00, C07H 21/00, C07K 14/00, C12N 5/06, C12N 15/87, A61P 43/00, A61K 39/00, C12N 7/00, A61K 35/12
US Classification:
424 852, 536 231, 530350, 435325, 4352351, 424 9321, 4241841, 435456
Abstract:
T-cell receptors that recognize MART-1 antigen are provided. The TCRs can be used, for example, to treat patients suffering from melanoma.
Mart-1 T Cell Receptors
US Patent:
8552150, Oct 8, 2013
Filed:
Feb 17, 2012
Appl. No.:
13/399922
Inventors:
Lili Yang - Pasadena CA, US
David Baltimore - Pasadena CA, US
Pin Wang - Pasadena CA, US
James Economou - Pacific Palisades CA, US
Antoni Ribas - Los Angeles CA, US
David Baltimore - Pasadena CA, US
Pin Wang - Pasadena CA, US
James Economou - Pacific Palisades CA, US
Antoni Ribas - Los Angeles CA, US
Assignee:
California Institute of Technology - Pasadena CA
Regents of the University of California - Oakland CA
Regents of the University of California - Oakland CA
International Classification:
C07K 14/00
US Classification:
530350, 435325
Abstract:
T-cell receptors that recognize MART-1 antigen are provided. The TCRs can be used, for example, to treat patients suffering from melanoma.